Does Aetna Cover Trulicity?

How Aetna Classifies Trulicity on Its Formulary

Aetna places Trulicity on its commercial formularies under preferred brand or non-preferred brand tiers, depending on the specific plan document. The tier assignment directly determines your out-of-pocket cost.

Preferred Brand vs. Non-Preferred Brand Placement

On Aetna's 2025-2026 national preferred drug lists, dulaglutide appears as a covered GLP-1 receptor agonist for type 2 diabetes management. Aetna commercial PPO and HMO plans most commonly list Trulicity at Tier 3 (preferred brand), though some employer-sponsored plans shift it to Tier 4 (non-preferred brand) when the plan sponsor negotiates different formulary terms.

Tier 3 placement typically means a copay between $35 and $75 per 30-day supply. Tier 4 placement raises that range to $75 to $150, or a coinsurance model where you pay 25% to 40% of the drug's negotiated price [1].

Medicare Advantage Formulary Differences

Aetna Medicare Advantage Part D plans also cover Trulicity, but formulary tiers differ from commercial plans. Under the 2025 Aetna Medicare Part D formulary, dulaglutide sits on the Specialty or Non-Preferred Brand tier for most regional plans. The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D spending, which took full effect in 2025, limits total yearly exposure for Medicare beneficiaries regardless of tier placement [2].

During the coverage gap (formerly the "donut hole"), Medicare patients now benefit from manufacturer discounts and federal subsidies that keep costs predictable. Patients who reach the catastrophic phase pay $0 for covered drugs under the updated benefit structure.

Prior Authorization Requirements for Trulicity Under Aetna

Aetna requires prior authorization for Trulicity across nearly all plan types. This is standard practice for GLP-1 receptor agonists given their cost and the availability of lower-cost diabetes medications.

What Aetna's PA Criteria Typically Include

Aetna's clinical policy bulletins outline specific criteria your prescriber must document. The standard requirements include a confirmed diagnosis of type 2 diabetes mellitus with HbA1c above 7.0% despite lifestyle modifications, current or prior use of metformin (unless contraindicated or not tolerated), and documentation that the prescriber is an endocrinologist or that the primary care physician manages the patient's diabetes care [3].

Some Aetna plans enforce step therapy. This means your doctor must show that you tried and failed (or cannot tolerate) metformin before Aetna will approve Trulicity. A few plans also require trial of a sulfonylurea or an SGLT2 inhibitor. The American Diabetes Association's 2024 Standards of Care support GLP-1 receptor agonists as second-line therapy after metformin for patients with established atherosclerotic cardiovascular disease, and as a reasonable second-line choice for most other patients with type 2 diabetes [4].

How Long Approval Takes

Most prior authorization decisions from Aetna come within 72 hours for non-urgent requests. Urgent requests (when delaying treatment poses serious health risk) receive a decision within 24 hours. If denied, your prescriber can file a peer-to-peer review or a formal appeal. Denials often stem from incomplete documentation rather than true clinical ineligibility.

Your prescriber's office handles the PA submission. Ask them to include your most recent HbA1c value, a list of previously tried diabetes medications with dates and reasons for discontinuation, and any relevant cardiovascular history. The REWIND trial (N=9,901) demonstrated that dulaglutide 1.5 mg reduced major adverse cardiovascular events by 12% compared to placebo over a median 5.4 years in patients with type 2 diabetes, providing strong clinical justification for coverage [5].

What You Will Pay Out of Pocket

Your actual cost depends on your plan's tier assignment, deductible structure, and whether you qualify for copay assistance.

Commercial Plan Cost Estimates

For Aetna commercial plans with Trulicity at Tier 3, monthly copays typically range from $35 to $75 after the pharmacy deductible is met. Plans using coinsurance instead of flat copays charge 25% to 40% of the negotiated rate, which can mean $80 to $200 per fill depending on the pharmacy benefit manager's contracted price.

Lilly's Trulicity Savings Card offers eligible commercially insured patients a copay as low as $25 per monthly prescription, with a maximum annual benefit. Patients with government insurance (Medicare, Medicaid, Tricare) do not qualify for manufacturer copay cards per federal anti-kickback statute regulations. The savings card can be combined with Aetna commercial coverage, effectively reducing the out-of-pocket cost to the $25 floor for most fills [6].

Medicare and Medicaid Considerations

Medicare Part D patients on Aetna plans can expect Trulicity costs to vary by phase of coverage. During the initial coverage phase, copays or coinsurance apply based on tier. Once total out-of-pocket spending reaches $2,000 in 2025, the catastrophic phase begins and the patient pays $0 for the remainder of the year [2].

Medicaid coverage for Trulicity varies by state. Aetna manages Medicaid plans in several states, and each state Medicaid program maintains its own preferred drug list. Prior authorization requirements on Medicaid plans tend to be stricter, often requiring failure of two oral diabetes agents before a GLP-1 is approved.

Clinical Evidence Supporting Trulicity Coverage

Insurance coverage decisions rest partly on clinical trial data. Trulicity has a substantial evidence base across multiple phase III programs that support its formulary inclusion.

The AWARD Trial Program

The AWARD clinical trial program included nine randomized controlled trials evaluating dulaglutide across different patient populations and comparator drugs. AWARD-1 (N=978) showed that dulaglutide 1.5 mg reduced HbA1c by 1.51% at 26 weeks compared to 0.99% with exenatide twice daily and 0.46% with placebo [7]. AWARD-5 (N=1,098) compared dulaglutide head-to-head against sitagliptin, with dulaglutide 1.5 mg achieving a 1.10% HbA1c reduction versus 0.32% for sitagliptin at 52 weeks [8].

These efficacy margins contribute to the ADA's recommendation of GLP-1 receptor agonists as preferred second-line agents in specific clinical scenarios, which in turn supports insurance coverage decisions.

Cardiovascular Outcome Data From REWIND

The REWIND trial stands apart because it enrolled a broader population than most cardiovascular outcome trials for diabetes drugs. Only 31% of participants had established cardiovascular disease at baseline, making the results more generalizable. The primary composite endpoint (non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death) occurred in 12.0% of the dulaglutide group versus 13.4% of the placebo group (HR 0.88, 95% CI 0.79-0.99, P=0.026) over 5.4 years [5].

Dr. Hertzel Gerstein, the REWIND principal investigator, stated: "These findings suggest that dulaglutide reduces cardiovascular events in a broad range of people with type 2 diabetes, not just those who have already had a heart attack or stroke." This broader applicability strengthens the case for coverage without restricting access to only the highest-risk patients.

The FDA expanded Trulicity's label in 2020 to include a cardiovascular risk reduction indication based on REWIND data, which gave insurers including Aetna additional clinical rationale to maintain formulary coverage [9].

How Trulicity Compares to Other Covered GLP-1s on Aetna

Aetna covers multiple GLP-1 receptor agonists, and their relative tier positions affect which drug your doctor may prescribe first.

Aetna's GLP-1 Formulary Field

Ozempic (semaglutide) and Trulicity (dulaglutide) often share the same tier on Aetna commercial formularies, though some plans prefer one over the other based on rebate agreements. Rybelsus (oral semaglutide) appears on most Aetna formularies as a non-preferred brand. Victoza (liraglutide) has largely been displaced by newer agents on many formularies but remains covered.

The SUSTAIN-7 trial (N=1,201) compared semaglutide 0.5 mg and 1.0 mg against dulaglutide 0.75 mg and 1.5 mg, finding that semaglutide produced greater HbA1c reductions (1.5% vs. 1.1% at the higher doses) and more weight loss (6.5 kg vs. 3.0 kg) at 40 weeks [10]. This data may influence which GLP-1 your Aetna plan prefers, though formulary placement ultimately depends on negotiated pricing rather than efficacy alone.

When Your Plan Requires a Different GLP-1 First

If Aetna's formulary lists a different GLP-1 as preferred, your doctor may need to prescribe that agent first or submit a formulary exception request explaining why Trulicity is medically necessary for you specifically. Valid reasons include prior adverse reactions to the preferred agent, drug-drug interactions, or clinical features that favor dulaglutide (such as the cardiovascular indication supported by REWIND in patients without established ASCVD).

The ADA's 2024 Standards of Care do not rank individual GLP-1 receptor agonists in a strict hierarchy, noting that "the choice among available GLP-1 RAs should be individualized based on patient-specific factors, including cardiovascular risk, weight management goals, and patient preference for injection frequency" [4].

Steps to Get Trulicity Covered by Aetna

Getting coverage approved involves a predictable sequence that your prescriber's office and pharmacy will coordinate.

The Approval Process, Step by Step

First, your prescriber writes the Trulicity prescription and sends it to your pharmacy. The pharmacy runs it through Aetna's formulary system. If prior authorization is flagged (it almost always is), the pharmacy notifies your prescriber. Your prescriber's office then submits the PA request to Aetna, including clinical documentation. Aetna reviews and responds within 72 hours for standard requests.

If approved, you pick up the medication and pay your tier-based copay or coinsurance. If denied, your prescriber can request a peer-to-peer review with an Aetna medical director, submit additional documentation, or file a formal appeal. Second-level appeals go to an independent review organization if Aetna upholds the denial.

Tips to Avoid Delays

Ask your prescriber to include all required documentation with the initial PA submission rather than waiting for Aetna to request it. Ensure your recent HbA1c lab result (drawn within the past 3 months) is attached. If your plan has step therapy requirements, confirm that your medical records document prior metformin use, including start date, duration, dose, and reason for inadequate response or intolerance.

Check your specific Aetna plan's Summary of Benefits and Coverage document for the exact formulary tier. You can also call the number on the back of your Aetna member card and ask the pharmacy benefits team to confirm Trulicity's tier placement and PA requirements for your plan.

What to Do If Aetna Denies Trulicity Coverage

Denials happen. They are not always final.

Common Denial Reasons

The most frequent denial reasons include incomplete documentation (missing HbA1c or medication history), failure to meet step therapy requirements (no documented metformin trial), use for an off-label indication (such as weight loss in a patient without type 2 diabetes), or the prescriber requesting a dose not supported by the approved labeling.

Trulicity is FDA-approved only for type 2 diabetes and cardiovascular risk reduction in type 2 diabetes. It is not FDA-approved for weight management as a standalone indication, unlike semaglutide 2.4 mg (Wegovy) or tirzepatide (Zepbound). Aetna will typically deny Trulicity for weight loss without a concurrent type 2 diabetes diagnosis [9].

The Appeals Process

Your prescriber can request an expedited peer-to-peer review, which connects them directly with an Aetna medical director to discuss the clinical rationale. If the peer-to-peer does not resolve the issue, a formal Level 1 appeal can be filed within 180 days of the denial. Aetna must respond within 30 days for standard appeals or 72 hours for expedited appeals involving urgent clinical need.

If Aetna upholds the denial at Level 1, you have the right to an external review by an independent third party. The external reviewer's decision is binding on Aetna. According to data from the Kaiser Family Foundation, approximately 50% of internal insurance appeals for prescription drug denials result in a full or partial reversal of the original decision [11].

Dulaglutide Dosing and Administration Basics

Trulicity is administered as a once-weekly subcutaneous injection using a prefilled, single-use pen. The starting dose is 0.75 mg once weekly, which may be increased to 1.5 mg once weekly after at least 4 weeks if additional glycemic control is needed. A 3.0 mg and 4.5 mg dose were FDA-approved in 2020 for patients requiring further HbA1c or weight reduction beyond what 1.5 mg achieves [9].

The Endocrine Society's 2023 clinical practice guideline on pharmacologic management of obesity recommends GLP-1 receptor agonists for patients with type 2 diabetes and a BMI of 27 kg/m² or greater, noting that higher doses of dulaglutide (3.0 mg and 4.5 mg) produce dose-dependent weight loss of approximately 3% to 5% of body weight [12]. Aetna's coverage for the higher doses may require separate prior authorization or a step-edit from the 1.5 mg dose.

Dr. John Buse, Director of the Diabetes Center at the University of North Carolina, has noted: "The dose-response relationship with dulaglutide means clinicians should titrate to the dose that achieves the patient's glycemic and weight targets, rather than settling for the starting dose."

Inject Trulicity in the abdomen, thigh, or upper arm. Rotate injection sites each week. The pen does not require reconstitution or needle attachment. Store unused pens in the refrigerator at 2°C to 8°C; a pen may be kept at room temperature (up to 30°C) for up to 14 days.